|
1
|
Dunbar E and Yachnis AT: Glioma diagnosis:
Immunohistochemistry and beyond. Adv Anat Pathol. 17:187–201. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Young RM, Jamshidi A, Davis G and Sherman
JH: Current trends in the surgical management and treatment of
adult glioblastoma. Ann Transl Med. 3:1212015.PubMed/NCBI
|
|
3
|
Stylli SS, Howes M, MacGregor L, Rajendra
P and Kaye AH: Photodynamic therapy of brain tumours: Evaluation of
porphyrin uptake versus clinical outcome. J Clin Neurosci.
11:584–596. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stylli SS, Kaye AH, MacGregor L, Howes M
and Rajendra P: Photodynamic therapy of high grade glioma-long term
survival. J Clin Neurosci. 12:389–398. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hannenhalli S and Kaestner KH: The
evolution of Fox genes and their role in development and disease.
Nat Rev Genet. 10:233–240. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jackson BC, Carpenter C, Nebert DW and
Vasiliou V: Update of human and mouse forkhead box (FOX) gene
families. Hum Genomics. 4:345–352. 2010.PubMed/NCBI
|
|
7
|
Bassel-Duby R, Hernandez MD, Yang Q,
Rochelle JM, Seldin MF and Williams RS: Myocyte nuclear factor, a
novel winged-helix transcription factor under both developmental
and neural regulation in striated myocytes. Mol Cell Biol.
14:4596–4605. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Clark KL, Halay ED, Lai E and Burley SK:
Co-crystal structure of the HNF-3/fork head DNA-recognition motif
resembles histone H5. Nature. 364:412–420. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Durocher D and Jackson SP: The FHA domain.
FEBS Lett. 513:58–66. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shi X, Bowlin KM and Garry DJ: Fhl2
interacts with Foxk1 and corepresses Foxo4 activity in myogenic
progenitors. Stem Cells. 28:462–469. 2010.PubMed/NCBI
|
|
11
|
Carlsson P and Mahlapuu M: Forkhead
transcription factors: Key players in development and metabolism.
Dev Biol. 250:1–23. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bailey JM, Singh PK and Hollingsworth MA:
Cancer metastasis facilitated by developmental pathways: Sonic
hedgehog, Notch, and bone morphogenic proteins. J Cell Biochem.
102:829–839. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nieto MA, Sargent MG, Wilkinson DG and
Cooke J: Control of cell behavior during vertebrate development by
Slug, a zinc finger gene. Science. 264:835–839. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cano A, Pérez-Moreno MA, Rodrigo I,
Locascio A, Blanco MJ, del Barrio MG, Portillo F and Nieto MA: The
transcription factor snail controls epithelial-mesenchymal
transitions by repressing E-cadherin expression. Nat Cell Biol.
2:76–83. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang J, Mani SA, Donaher JL, Ramaswamy S,
Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A and
Weinberg RA: Twist, a master regulator of morphogenesis, plays an
essential role in tumor metastasis. Cell. 117:927–939. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cohen MS, Hussain HB and Moley JF:
Inhibition of medullary thyroid carcinoma cell proliferation and
RET phosphorylation by tyrosine kinase inhibitors. Surgery.
132:960–967. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhu Y and Parada LF: The molecular and
genetic basis of neurological tumours. Nat Rev Cancer. 2:616–626.
2002. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schwartzbaum JA, Fisher JL, Aldape KD and
Wrensch M: Epidemiology and molecular pathology of glioma. Nat Clin
Pract Neurol. 2:494–503. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al: Effects of radiotherapy with concomitant and
adjuvant temozolomide versus radiotherapy alone on survival in
glioblastoma in a randomised phase III study: 5-year analysis of
the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cloughesy TF, Cavenee WK and Mischel PS:
Glioblastoma: From molecular pathology to targeted treatment. Annu
Rev Pathol. 9:1–25. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Katoh M and Katoh M: Human FOX gene family
(Review). Int J Oncol. 25:1495–1500. 2004.PubMed/NCBI
|
|
24
|
Yang Y, Hou H, Haller EM, Nicosia SV and
Bai W: Suppression of FOXO1 activity by FHL2 through SIRT1-mediated
deacetylation. EMBO J. 24:1021–1032. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Murakami H, Aiba H, Nakanishi M and
Murakami-Tonami Y: Regulation of yeast forkhead transcription
factors and FoxM1 by cyclin-dependent and polo-like kinases. Cell
Cycle. 9:3233–3242. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Teh MT, Wong ST, Neill GW, Ghali LR,
Philpott MP and Quinn AG: FOXM1 is a downstream target of Gli1 in
basal cell carcinomas. Cancer Res. 62:4773–4780. 2002.PubMed/NCBI
|
|
27
|
Müller SM, Terszowski G, Blum C, Haller C,
Anquez V, Kuschert S, Carmeliet P, Augustin HG and Rodewald HR:
Gene targeting of VEGF-A in thymus epithelium disrupts thymus blood
vessel architecture. Proc Natl Acad Sci USA. 102:pp. 10587–10592.
2005; View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Reddy OL, Cates JM, Gellert LL, Crist HS,
Yang Z, Yamashita H, Taylor JA III, Smith JA Jr, Chang SS, Cookson
MS, et al: Loss of FOXA1 drives sexually dimorphic changes in
urothelial differentiation and is an independent predictor of poor
prognosis in bladder cancer. Am J Pathol. 185:1385–1395. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Badve S, Turbin D, Thorat MA, Morimiya A,
Nielsen TO, Perou CM, Dunn S, Huntsman DG and Nakshatri H: FOXA1
expression in breast cancer-correlation with luminal subtype A and
survival. Clin Cancer Res. 13:4415–4421. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mirosevich J, Gao N, Gupta A, Shappell SB,
Jove R and Matusik RJ: Expression and role of Foxa proteins in
prostate cancer. Prostate. 66:1013–1028. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jungert K, Buck A, von Wichert G, Adler G,
König A, Buchholz M, Gress TM and Ellenrieder V: Sp1 is required
for transforming growth factor-beta-induced mesenchymal transition
and migration in pancreatic cancer cells. Cancer Res. 67:1563–1570.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sun T, Wang H, Li Q, Qian Z and Shen C:
Forkhead box protein k1 recruits TET1 to act as a tumor suppressor
and is associated with MRI detection. Jpn J Clin Oncol. 46:209–221.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wu Y, Peng Y, Wu M, Zhang W, Zhang M, Xie
R, Zhang P, Bai Y, Zhao J, Li A, et al: Oncogene FOXK1 enhances
invasion of colorectal carcinoma by inducing epithelial-mesenchymal
transition. Oncotarget. 7:51150–51162. 2016.PubMed/NCBI
|
|
34
|
Fonkem E, Lun M and Wong ET: Rare
phenomenon of extracranial metastasis of glioblastoma. J Clin
Oncol. 29:4594–4595. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liwnicz BH and Rubinstein LJ: The pathways
of extraneural spread in metastasizing gliomas: A report of three
cases and critical review of the literature. Hum Pathol.
10:453–467. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pasquier B, Pasquier D, Lachard A, N'Golet
A, Panh MH and Couderc P: Extraneural metastasis of central nervous
system tumours (author's transl). Bull Cancer. 66:25–28. 1979.(In
French). PubMed/NCBI
|
|
38
|
Müller C, Holtschmidt J, Auer M, Heitzer
E, Lamszus K, Schulte A, Matschke J, Langer-Freitag S, Gasch C,
Stoupiec M, et al: Hematogenous dissemination of glioblastoma
multiforme. Sci Transl Med. 6:247ra1012014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen F, Xiong W, Dou K and Ran Q:
Knockdown of FOXK1 suppresses proliferation, migration and invasion
in prostate cancer cells. Oncol Res. 25:1261–1267. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wu M, Wang J, Tang W, Zhan X, Li Y, Peng
Y, Huang X, Bai Y, Zhao J, Li A, et al: FOXK1 interaction with FHL2
promotes proliferation, invasion and metastasis in colorectal
cancer. Oncogenesis. 5:e2712016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Peng Y, Zhang P, Huang X, Yan Q, Wu M, Xie
R, Wu Y, Zhang M, Nan Q, Zhao J, et al: Direct regulation of FOXK1
by C-jun promotes proliferation, invasion and metastasis in gastric
cancer cells. Cell Death Dis. 7:e24802016. View Article : Google Scholar : PubMed/NCBI
|
